Moreover, this in-depth analysis also revealed a characteristic expression patterns of CX3CL1 (fractalkine) and its receptor CX3CR1 that distinguished PA I from AS II, AS III and GBM IV. This evidence concerns the gene CX3CL1 and glioblastoma.